S 23 10 mg

S 23 10 mg contains mastorin (S-23), a SARM. It has no approved medical use. In non-medical bodybuilding contexts, it is commonly referenced for muscle hardening and body recomposition during cutting phases, though such use falls outside approved indications and carries substantial health risks.

S-23 has a half-life commonly referenced as approximately 12 hours, supporting twice-daily dosing. In non-medical contexts, it is typically referenced as being taken twice daily, often morning and evening, to maintain stable blood levels.

Yes, absolutely. PCT is non-negotiable with S-23 because HPG shutdown is the expected outcome, not a rare side effect. S-23 was specifically investigated as a male contraceptive and demonstrated reversible suppression of spermatogenesis in animal studies. Agents such as Clomid or Nolvadex are commonly referenced for PCT.

S-23 is a nonsteroidal SARM that binds the androgen receptor with high affinity (Ki 1.7 nM) and full agonist activity. It selectively activates androgenic signaling in muscle and bone, and was originally developed as a male hormonal contraceptive due to its potent suppression of gonadotropins and spermatogenesis.

S-23 reaches steady state within 3–4 days of twice-daily dosing, so front-loading provides no additional benefit. In non-medical contexts, users often report noticeable hardening and vascularity effects within the first 1–2 weeks, with body composition changes developing over a 6–10 week cycle.

S-23 is widely regarded as one of the most potent and suppressive SARMs available. Community comparisons place it significantly above ostarine and RAD-140 in terms of strength of effect and suppression. However, potency comes with proportional risk, and S-23 is not recommended for beginners.

Both are SARMs, but community discussion generally places S-23 in a higher potency tier than RAD 140. S-23 is also significantly more suppressive, with a well-documented impact on LH and FSH. RAD-140 is often described as more manageable for intermediate users.

S-23 is substantially more potent and suppressive than MK 2866 (ostarine). Ostarine is often described as a beginner SARM with milder effects and less suppression, while S-23 is considered an advanced compound for experienced users willing to manage full PCT and regular bloodwork.

S-23 has no established human dosage. In non-medical contexts, 10 mg per day is commonly referenced as a conservative starting point, with reference ranges extending to 30 mg per day. Research community protocols often start at the lower end for 2–4 weeks to assess individual response. S 23 10 mg is labeled at 10 mg per tablet.

S 23 10 mg is labeled at 10 mg of mastorin per tablet. It is supplied in a 100-tablet package, giving 1,000 mg of total labeled mastorin content.

Yes. Published laboratory reports for S 23 10 mg are available. The most recent report dated April 18, 2025 measured the product at 12.43 mg per tablet, equivalent to 124.30% of its 10 mg label claim. Complete reports can be viewed in the Lab Reports tab.

No. S-23 is not approved by the FDA for any human indication and is classified as an unapproved new drug when sold for human consumption. It is prohibited by WADA at all times and is detectable in urine for up to 28 days following oral administration.